Post-translational modifications (PTM) by members of the Ubiquitin (Ub) family represent an efficient way to regulate almost every biological process. Defects in this homeostatic equilibrium, result in pathologies such as cancer, neurodegeneration, inflammation or multiple infections. For this reason, this research area has become very attractive for fundamental scientists as well as for the pharmaceutical industry aiming to identify potential targets for therapeutic intervention. Our one-day symposium will therefore focus on the potential developments with regards to the druggability of…